Alex Huybens appointed as Chief Executive Officer (CEO) of HAL Allergy Holding B.V. and HALIX B.V.

Leiden (The Netherlands, 01.07.2021) – As of 1 July 2021, the Supervisory Board of the HAL Allergy Group has appointed Alex Huybens as Chief Executive Officer (CEO) and Member of the Board of HAL Allergy Holding B.V., as well as CEO of HALIX B.V.

Alex Huybens, Master of Business Administration (MBA) and with a degree in Engineering, started his career at HAL Allergy in 2003. In the following years, he took responsibility in several positions in Production, Supply Chain Management, Technical Services, Biochemistry, Microbiology and R&D functions.

“Alex Huybens is the right business leader for HAL Allergy and HALIX”, says Harry Flore, Chairman of the Supervisory Board of the Group and former CEO of the Company. “Alex Huybens has a proven track record of translating business opportunities into value-creating growth.”

Alex Huybens took over the role as Chief Operations Officer in the newly established HALIX B.V. creating a Contract Development and Manufacturing Organization (CDMO) for GMP-manufacturing of biologics for small- and midsized biotech companies as well as for big pharma (on BSL2 and BSL3-level). Today, HALIX is one of the leading European CDMOs producing drug substance/API for clinical trials as well as for commercial use, including the COVID-19 vaccine for AstraZeneca.

“In my role as CEO of HAL Allergy and HALIX, my focus will be on realizing the opportunities the markets are offering for us. While the further development of HALIX including the expansion
towards cell & gene therapy is on top of my list, HAL Allergy through its existing immunotherapies as well as its pipeline portfolio holds vast opportunities for us. By forming a bridge between both
companies, I want to be the number one contact for clients, partners as well as our employees.”

HAL Allergy specializes in the development, production and distribution of allergen immunotherapies for the treatment and prevention of allergic diseases. With a highly competitive product portfolio, including subcutaneous and sublingual products, and a future-oriented pipeline portfolio, HAL Allergy works intensively in collaboration with the world’s allergy specialists. Through its pipeline portfolio (including AIT candidates for food, especially peanut, in clinical and preclinical stage), HAL Allergy is well-positioned to meet its growth ambitions and enhance the quality of life for millions of people.

Alex Huybens, will head the Board of Directors of the HAL Allergy Group with the co-members Florian Rösch (CCFO), Dr. Hans van Schijndel (CRDO) and Gareth West (COO).

About HALIX

HALIX B.V. is a biopharmaceutical contract development and manufacturing organization (CDMO) for biologics enabling the treatment and prevention of life-threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substances and drug products. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies. The company opened its state-of-the-art 6,700 m2 GMP manufacturing facility in 2019, offering 1,000L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX belongs to the family-owned Droege Group AG.
More information is available on: www.halix.nl

About HAL Allergy

HAL Allergy Group is active in the field of biopharmaceuticals and is located at the Bio Science Park in Leiden, The Netherlands. Our core business is the development and manufacturing of therapies and diagnostics for allergic diseases. With offices in major European countries, HAL Allergy is one of the European top players in the allergy immunotherapy business. Established in 1959 HAL Allergy has long experience in developing, producing and selling allergy therapies with an immuno-modulatory effect causing a reduction in symptoms and long-term disease suppression. The allergy therapies are used against common allergies such as hay fever, house dust mites allergy and allergic reactions towards wasp or bee stings. The main shareholder of HAL Allergy Group is Droege Group AG, based in Düsseldorf, Germany.
More information is available on: www.hal-allergy.com